EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Time Series Methods to Assess the Impact of Regulatory Action: A Study of UK Primary Care and Hospital Data on the Use of Fluoroquinolones

Yuchen Guo iD, Berta Raventós, Martí Català, Leena Elhussein, Kim López-Güell, Eng Hooi Tan, Albert Prats-Uribe, Daniel Dedman, Wai Yi Man, Hezekiah Omulo, Antonella Delmestri, Jennifer C E Lane und 12 weitere

Pharmacoepidemiology and Drug Safety · 2024

DOI: 10.1002/pds.70022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Yuchen Guo und 23 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Statistics in Medicine, University of Oxford, Botnar Research Centre, Oxford, UK. Hauptthemen laut MEDLINE: Fluoroquinolones, Primary Health Care, Interrupted Time Series Analysis, Anti-Bacterial Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, UKRI Strategic Priority Fund (SPF) - Alleviate Pain Data Hub, Medicines and Healthcare Products Regulatory Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To illustrate the interest in using interrupted time series (ITS) methods, this study evaluated the impact of the UK MHRA's March 2019 Risk Minimisation Measures (RMM) on fluoroquinolone usage.

Methods

Monthly and quarterly fluoroquinolone use incidence rates from 2012 to 2022 were analysed across hospital care (Barts Health NHS Trust), primary care (Clinical Practice Research Datalink (CPRD) Aurum and CPRD GOLD), and linked records from both settings (East Scotland). Rates were stratified by age (19–59 and ≥ 60 years old). Seasonality‐adjusted segmented regression and ARIMA models were employed to model quarterly and monthly rates, respectively.

Results

Post‐RMM, with segmented regression, both age groups in Barts Health experienced nearly complete reductions (> 99%); CPRD Aurum saw 20.19% (19–59) and 19.29% ( 60) reductions; no significant changes in CPRD GOLD; East Scotland had 45.43% (19–59) and 41.47% ( 60) decreases. Slope analysis indicated increases for East Scotland (19–59) and both CPRD Aurum groups, but a decrease for CPRD GOLD's 60; ARIMA detected significant step changes in CPRD GOLD not identified by segmented regression and noted a significant slope increase in Barts Health's 19–59 group. Both models showed no post‐modelling autocorrelations across databases, yet Barts Health's residuals were non‐normally distributed with non‐constant variance.

Conclusions

Both segmented regression and ARIMA confirmed the reduction of fluoroquinolones use after RMM across four different UK primary care and hospital databases. Model diagnostics showed good performance in eliminating residual autocorrelation for both methods. However, diagnostics for hospital databases with low incident use revealed the presence of heteroscedasticity and non‐normal white noise using both methods.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluoroquinolonesPrimary Health CareInterrupted Time Series AnalysisAnti-Bacterial AgentsHumansMiddle AgedUnited KingdomAdultYoung AdultDatabases, FactualHospitals

Stichwörter der Autor:innen

autoregressive integrated moving averagefluoroquinolonesimpactinterrupted time seriesregulatory interventionsrisk minimisation measuressegmented regression

Substanzen

FluoroquinolonesAnti-Bacterial Agents

Autor:innen und Institutionen

  • Centre for Statistics in Medicine, University of Oxford, Botnar Research Centre, Oxford, UK.
  • Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
  • Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Valles), Barcelona, Spain.
  • Medicines and Healthcare Products Regulatory Agency, London, UK.
  • Barts Bone and Joint Health, Queen Mary University of London, London, UK.
  • Barts Health NHS Trust, NHS Trust, London, UK.

ORCID-Profile: Yuchen Guo, Daniel Prieto-Alhambra

Förderung

  • Medical Research Council
  • UKRI Strategic Priority Fund (SPF) - Alleviate Pain Data Hub
  • Medicines and Healthcare Products Regulatory Agency
  • NIHR Oxford Biomedical Research Centre

Zitieren

APA

Guo, Y., Raventós, B., Català, M., Elhussein, L., López-Güell, K., Tan, E. H., Prats-Uribe, A., Dedman, D., Man, W. Y., Omulo, H., Delmestri, A., Lane, J. C. E., Rahman, U., Griffin, X. L., Gao, C., Cole, C., Batty, P., Connelly, J., Booth, H., …, & Jödicke, A. M. (2024). Time Series Methods to Assess the Impact of Regulatory Action: A Study of UK Primary Care and Hospital Data on the Use of Fluoroquinolones. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70022

Vancouver

Guo Y, Raventós B, Català M, Elhussein L, López-Güell K, Tan EH, et al. Time Series Methods to Assess the Impact of Regulatory Action: A Study of UK Primary Care and Hospital Data on the Use of Fluoroquinolones. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.70022

BibTeX
@article{Guo2024,
  author = {Guo, Yuchen and Raventós, Berta and Català, Martí and Elhussein, Leena and López-Güell, Kim and Tan, Eng Hooi and Prats-Uribe, Albert and Dedman, Daniel and Man, Wai Yi and Omulo, Hezekiah and Delmestri, Antonella and Lane, Jennifer C E and Rahman, Usama and Griffin, Xavier L and Gao, Chuang and Cole, Christian and Batty, Patrick and Connelly, John and Booth, Helen and Cave, Alison and Donegan, Katherine and Prieto-Alhambra, Daniel and Burn, Edward and Jödicke, Annika M},
  title = {Time Series Methods to Assess the Impact of Regulatory Action: A Study of UK Primary Care and Hospital Data on the Use of Fluoroquinolones},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2024},
  doi = {10.1002/pds.70022}
}
Kostenlos starten →